Nuformix welcomes Dr. Julian Gilbert to its Board as Non-Executive Director

– UK, Redcar –  Nuformix plc (LON: NFX), a drug re-purposing specialist, today announced the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director effective immediately.

Julian will be appointed as a member of the Nomination & Audit Committees.

“It’s a pleasure for us to welcome Julian to the Board. Julian’s knowledge and experience will be extremely valuable as the Company moves forward with its near-term strategic priorities focussed on business development and licensing opportunities,” said Executive Chairman, Dr Chris Blackwell. 

About Dr Julian Gilbert

Julian has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at several companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc and Smith Kline & French. Most recently, Julian was co-founder and CEO of Acacia Pharma Group plc, raising c.£100m in private and public funding and leading its flotation on Euronext in 2018. Julian resigned from Acacia on 31 July 2019. Before Acacia, he was co-founder and Commercial Director of Arakis Limited which was sold to Sosei in 2005 for £107 million. Julian has worked in business development since 1992 and has led multiple business development projects.

Commenting on his appointment, Dr Julian Gilbert said: “I am delighted to be joining the Board of Nuformix, and look forward to supporting the Company achieve key strategic objectives.”

Julian has a degree in pharmacy and a PhD in pharmaceutics, both from the University of Nottingham.

About Nuformix

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix’s model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.

Nuformix plc shares are traded on the London Stock Exchange’s Official List under the ticker: NFX.

For more information: https://nuformix.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.